Definitive Contract HHSN272201500014C

This is a $27,032,719.27 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID) to Spero Therapeutics, Inc. to advance the clinical and non-clinical development of an antibiotic candidate. The contract is not set aside. The contract originated from a NIAID Broad Agency Announcement (BAA) soliciting proposals for the advanced development of vaccine candidates, therapeutic products, and diagnostics to address biodefense, antimicrobial...

The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), awarded a $18,523,063 definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. (also doing business as Forge Therapeutics) to develop an LPXC inhibitor for the treatment of multidrug-resistant gram-negative urinary tract infections. This work will be performed in San Diego, California over 14 months. There is no set-aside designation associated with this contract....

The Department of Health and Human Services' National Institutes of Health's National Institute of Allergy and Infectious Diseases awarded a $300,000 firm fixed price definitive contract to Nference Inc., a for-profit organization located in Cambridge, Massachusetts, to deliver on SBIR Topic 111 with a completion date of September 15, 2023. No set-aside designation was used for this award. The contract will support the National Institute of Allergy and Infectious Diseases' mission to conduct and...

This is a $28,613,040.00 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health (NIH), to Crestone, Inc., a biotech company specializing in research on treatments for antibiotic-resistant bacterial infections. The contract supports Crestone's work to synthesize antibiotic compounds, test their activity, and advance lead candidates through investigational new drug filing and early...

This is a $4,469,522.01 cost-plus-fixed-fee definitive contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency, to Agile Sciences, Inc., a small disadvantaged business. The contract is for "Targeting Therapeutics Development to Relieve Bottlenecks: Optimizing Lead Therapeutic Compounds Against Infectious Pathogens" and has an ultimate completion date of October 15, 2018. The contract was awarded on June 30, 2015 and was not set aside.

This federal contract award was issued by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. Department of Health and Human Services. The $99,299 cost-plus-fixed-fee delivery order was placed under the Therapeutics Against Infectious Diseases Phase 1 IDIQ contract, which funds Phase I clinical trials for therapeutic products targeting infectious diseases. The prime contractor is Dynport Vaccine Company LLC, a subsidiary of General Dynamics...

This is a $3,624,974 cost-plus-fixed-fee contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a component of the Department of Health and Human Services, to Trius Therapeutics, Inc. for the "DEVELOPMENT OF THERAPEUTIC MEDICAL COUNTERMEASURES FOR BIODEFENSE AND EMERGING INFECTIOUS DISEASES". The contract has a period of performance from September 16, 2013 to September 15, 2015, with a ceiling value of $845,876.06. There is no set-aside for this award....

This is a Definitive Contract awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a division of the U.S. Department of Health and Human Services, to Metallopharm LLC, a small disadvantaged business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $224,868.00, is for the development of a formulation for the oral delivery of the antibiotic Capreomycin. The contract has a firm fixed price pricing type and a total small...

This contract was awarded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. Department of Health and Human Services, to the Southern Research Institute, a corporate entity tax-exempt non-profit organization. The contract is a Delivery Order under the In Vitro Assessments of Antimicrobial Activity (IVAAA) Indefinite Delivery/Indefinite Quantity (ID/IQ) contract vehicle. The $1,275,123.00 cost-plus-fixed-fee contract is for evaluating therapeutic product...

The National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the U.S. government, has awarded a $306,500.00 firm fixed price definitive contract to Fox Chase Chemical Diversity Center Inc., a for-profit pharmaceutical organization. The contract, which does not have a set-aside designation, is for SBIR Topic 134 and has an ultimate completion date of November 14, 2025. Fox Chase Chemical Diversity Center Inc. is an experienced federal contractor, having received...